Clinical Decision Support Software Utilizing Artificial Intelligence and Machine Learning; Updated Regulatory Framework
Summary
This proposed rule establishes an updated regulatory framework for clinical decision support software that uses artificial intelligence and machine learning. It creates a tiered classification system based on the clinical risk level of the AI's intended use and introduces a predetermined change control plan pathway that allows manufacturers to update algorithms without requiring new premarket submissions for each modification.
Key Points
- 1Creates three tiers of regulatory oversight based on clinical risk of the AI/ML software
- 2Establishes a predetermined change control plan for algorithm updates within defined boundaries
- 3Requires transparency labeling showing training data demographics and known limitations
- 4Mandates real-world performance monitoring and periodic reporting to the FDA
- 5Exempts low-risk clinical decision support tools that meet specific transparency criteria
Impact Assessment
If you are a healthcare software manufacturer, this means you'll need to classify your AI clinical decision support tools by risk level and can update algorithms more flexibly through a predetermined change control plan instead of seeking FDA approval for each modification.
National
Moderate
Key Dates
June 2, 2025
Regulatory Connections
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.
The Digest Network
AI Comment Drafter
Describe your concern and we'll help you draft a substantive comment.
AI-generated draft. Always review and edit before submitting. Replace all [bracketed placeholders] with your specific details. Your comment should reflect your genuine views and experience.